Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2020)

Monopar Therapeutics' Profit After Tax history spans 4 years, with the latest figure at -$2.1 million for Q4 2020.

  • For Q4 2020, Profit After Tax fell 76.36% year-over-year to -$2.1 million; the TTM value through Dec 2020 reached -$6.3 million, down 49.23%, while the annual FY2024 figure was -$15.6 million, 85.51% down from the prior year.
  • Profit After Tax for Q4 2020 was -$2.1 million at Monopar Therapeutics, down from -$1.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$372915.0 in Q1 2017 and bottomed at -$14.9 million in Q3 2017.
  • The 4-year median for Profit After Tax is -$898080.5 (2018), against an average of -$1.9 million.
  • The largest YoY upside for Profit After Tax was 95.7% in 2018 against a maximum downside of 135.0% in 2018.
  • A 4-year view of Profit After Tax shows it stood at -$713583.0 in 2017, then fell by 24.79% to -$890461.0 in 2018, then tumbled by 35.53% to -$1.2 million in 2019, then plummeted by 76.36% to -$2.1 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Profit After Tax are -$2.1 million (Q4 2020), -$1.6 million (Q3 2020), and -$1.4 million (Q2 2020).